(firstQuint)A Study to Test 2 Doses of the HRV Vaccine Given With or Without OPV in Healthy Infants in Bangladesh.

 "The study will have four groups: Group HRV + OPV, Group HRV alone, Group Placebo + OPV and Group Placebo alone.

 Two-dose immunisation will be administered in healthy infants at approximately 12 and 16 weeks of age.

 Immunogenicity, reactogenicity and safety relative to the placebo will also be evaluated.

 Treatment allocation: randomized (2:2:1:1).

 Routine EPI vaccines should be administered during the study following the EPI recommendation in Bangladesh.

".

 A Study to Test 2 Doses of the HRV Vaccine Given With or Without OPV in Healthy Infants in Bangladesh@highlight

The main objective of this study is to provide immunogenicity data for GSK Biologicals' HRV vaccine when co-administered with OPV or when given alone (HRV vaccine dose given 15 days after the OPV dose).

